1. Prostate Specific Antigen Testing Market Overview
2. Prostate Specific Antigen Testing Market Executive Summary
3. PSA Testing Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End user profiling
3.2.3. Patent Analysis
3.2.4. Top 5 Financials Analysis
4. PSA Testing Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. PSA Testing Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunities Analysis
5.3. Product/Market Life Cycle Analysis
6. PSA Testing Market – By Type
6.1. Free Prostate Specific Antigen Test
6.2. Complex Prostate Specific Antigen Test
6.3. Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction Test
7. Global PSA Testing Market - Geographic Analysis
7.2. North America
8. Prostate Specific Antigen Testing Market Entropy
8.1. New Product Launches
8.2. M&As, Collaborations, JVs and Partnerships
9. Prostate specific antigen testing market Company Profiles (Overview, Financials, SWOT Analysis – Top 5 Companies, Developments, Product Portfolio)
9.1. Abbott Laboratories, Inc.
9.2. Bayer AG
9.3. Beckman Coulter, Inc.
9.4. GE Helathcare
9.5. GlaxoSmithKline, plc.
9.6. Novartis Pharma AG.
9.7. UroLogix, Inc.
9.8. Bristol - Myers Squibb Company
9.9. AstraZeneca plc.
9.10. Johnson & Johnson Diagnostics
9.11. BioChem Pharma
9.12. Pharmacia Delfia
9.13. Roche Diagnostics
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.5. Compilation of Expert Insights
Prostate Specific Antigen is secreted by epithelial prostatic cells. The primary function of PSA is to break down high molecular weight protein of the seminal coagulum into smaller polypeptides. The PSA is present in serum which is used to detect prostate cancer. There is a continuous circulation of PSA in the blood.
The PSA testing is gaining popularity among clinicians and hospitals as the number of people affected by prostate cancer in the age bracket of 40-50 years is on a rise. A high level of PSA is an indicator of possible prostate cancer. However, there are other physical conditions which might lead to an increase in PSA levels.
The number of people affected by prostate cancer in 2014 was 233,000 from 417,000 in 2012. The reason for this sharp decline in prostate cancer incidences is due to effective PSA testing. The global prostate specific antigen testing market was close to $250 million in 2014. The population in the age bracket of 50-64 years are more likely to develop prostate cancer. Prostate Cancer is the fourth most common cancer. The need for PSA testing has seen an upward surge. The North America region is going to see the highest increase due to better focus on healthcare. The Europe region has different guidelines and policies for PSA testing in different countries. Such scenario has led to a decreased use of PSA testing in Europe region.
Prostate specific antigen testing market size and forecast is provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the PSA testing market and future opportunities are provided in the report. This report on the global PSA testing market identifies many such insights and M&A opportunities, besides providing a detailed analysis of the PSA testing market.